紫杉醇脂质体治疗老年非小细胞肺癌Ⅱ期临床研究  

Phase Ⅱ trial of paclitaxel liposome in elderly patients with non-small cell lung cancer

作　　者：涂玲俐[1] 陈永顺[1] 丁振宇[1] 徐泳[1] 周麟[1] 刘咏梅[1] 李潞[1] 朱江[1] 黄媚娟[1] 王瑾[1] 任莉[1] 侯梅[1] 卢铀[2] 

机构地区：[1]四川大学华西医院肿瘤中心胸部肿瘤科,成都610041 [2]四川大学华西医院生物治疗国家重点实验室,610041

出　　处：《临床肿瘤学杂志》2009年第4期314-318,共5页Chinese Clinical Oncology

摘　　要：目的:治疗老年非小细胞肺癌(NSCLC)目前推荐第三代单药化疗,紫杉醇脂质体单药治疗老年(≥70岁)NSCLC的疗效及不良反应未见前瞻性研究报道,本研究旨在评价其治疗老年NSCLC的疗效及安全性。方法:26例经病理或细胞学确诊的老年NSCLC患者,有21例患者合并程度不等的各种并发症。采用紫杉醇脂质体135mg/m2,静脉滴注3h,d1,21天为1周期。结果:入组26例患者,均可评价疗效及不良反应。3例部分缓解,9例病情稳定,有效率11.5%,疾病控制率42.3%。中位生存期12.5个月。接受紫杉醇脂质体化疗4周期及以上患者的疾病控制率达66.7%,化疗不足4周期患者的疾病控制率为18.2%。ⅠB～Ⅲ期及Ⅳ期患者化疗后疾病控制率分别为38.5%和53.8%,中位生存期分别为13.8个月和10.0个月。主要不良反应有骨髓抑制,胃肠道反应及肝功能异常,多为Ⅰ～Ⅱ度反应。无化疗相关性死亡。结论:紫杉醇脂质体单药治疗老年(≥70岁)NSCLC毒性低,疗效较好,是老年肺癌单药化疗安全可靠的一种治疗选择。Objective：Standard chemotherapy for elderly patients with non-small cell lung cancer（NSCLC） remains undefined.The study was to evaluate the efficacy and tolerability of the paclitaxel liposome in elderly patients with NSCLC.Methods：Twenty-six patients aged ≥70 years were confirmed diagnosis of NSCLC,and tewnty-one have comorbid conditions.All patients received paclitaxel liposome 135mg/m^2as a 3-h infusion on day 1.Treatment was repeated every 21 days.Results：Among 26 patients,all were evaluated for response and toxicity.The overall response rate was 11.5% with complete and partial response rate of 0% and 11.5%,respectively,the disease control rate was 42.3%.The median overall survival was 12.5 months.The disease control rate of patients who received 4 cycles or more of chemotherapy was 66.7% versus 18.2% compared with those received under 4 cycles of chemotherapy.The disease control rates for stage ⅠB-Ⅲ and Ⅳ patients were 38.5% and 53.8%,and the median survival was 13.8 months and 10.0 months,respectively.Adverse events were generally mild,mostly including myelosuppression,gastrointestinal and liver function impairment.There was no treatment-related death.Conclusion：The treatment of paclitaxel liposome shows an effective antitumor activity and a favorable toxicity profile in elderly patients with NSCLC.

关 键 词：紫杉醇脂质体 非小细胞肺癌 老年 化学治疗 

分 类 号：R734.2[医药卫生—肿瘤]